Multiple myeloma
Multiple myeloma
Updated: 09/04/2024
© Jun Wang, MD, PhD
General features
- Plasma cell neoplasm
- Clinical variants
Asymptomatic (smoldering) myeloma: NO related
organ or tissue impairment
Non-secretory myeloma: NO M-protein by
electrophoresis or immunofixation; clinical features similar to secretory
myeloma except for low incidence of renal insufficiency and hypercalcemia
Plasma cell leukemia: Clonal plasma cells >
20% of the leukocyte differential count; aggressive disease
Clinical presentations
- Widespread lytic bone lesions, bone pain, pathological fracture
- Renal insufficiency: caused by toxicity of light chains to renal epithelium
- Amyloidosis
- Hyperviscosity syndrome
- Increased risk of infection, most common cause of death
Key pathogenesis
- DKK1 and FRP2: Inhibit Wnt, blocking bone formation
- Elevated RANKL, promotes osteoclasts activity, similar to giant cell tumor of bone
- Suppressed OPG
Key Laboratory findings
- Monoclonal gammopathy (M spikes)
- M proteins in serum or urine (Most common IgG, followed by IgA)
- Bence Jones proteins in urine
- Elevated immunoglobulin: > 3g/dl (IgG) or >2.5g/dl (IgA)
- Rouleaux formation
- Hypercalcemia
- Abnormal renal functions
Key morphological features
- Plasma cell infiltrate of marrow or other tissue
- Abnormal plasma cells: Perinueclear clearing
- Mott cells: Plasma cells with grapelike cytoplasmic inclusions (Russell bodies)
- Russell bodies: Cytoplasmic cherry red refractive round bodies
- Dutcher bodies: Intranuclear crystalline rods
Markers
- Positive: CD38, CD138, light chain restriction
- Negative: CD19, CD20
Diagnostic criteria
- A bone marrow aspirate or biopsy showing that at least 10 percent of the cells are plasma cells or the presence of a plasma cell tumor (called a plasmacytoma)
- Plus at least one of the following two features:
Evidence of damage to the
body as a result of the plasma cell growth, such as severe bone damage, kidney
failure, anemia, or high calcium in the blood, and/or
Detection of one of the
following findings: ≥60% plasma cells in the bone marrow; free light
chain ratio of 100 or more (provided involved FLC level is at least 100 mg/L);
or MRI showing more than one lesion (involving bone or bone marrow)
- Various
- IgH translocations
- Myc, p53, RAS, RB1, etc
Negative prognosis indicator
- Elevated IL-6: Promotes tumor cell survival
- Hypercalcemia
- Bence Jones proteinemia
- Renal impairment
- Translocation t(14;16), t(14;20), t(4;14) and deletion chromosome 17p (p53)
Back to contents
Comments
Post a Comment